Sign in Subscribe
Pharmaceutical industry

Geron Corp. and Merck Collaborate to Develop Telomerase Cancer Vaccine

Strategic Insights

— 1 min read

Geron Corp., a leader in the development of telomerase-based cancer therapies, has entered into a collaboration and license agreement with pharmaceutical giant Merck & Co. to develop a cancer vaccine targeting telomerase. This strategic alliance combines Geron's expertise in telomerase biology with Merck's expertise in vaccine technologies, aiming to create a novel cancer vaccine that has the potential to address a broad range of cancers. Under the agreement, Geron will receive upfront payments, milestone payments, and royalties, as well as equity investment from Merck in Geron's next round of financing.

Key Takeaways:

  • Geron Corp. and Merck & Co. have entered into a collaboration and license agreement to develop a cancer vaccine targeting telomerase.
  • The agreement provides Geron with upfront payments, milestone payments, and royalties, as well as equity investment from Merck.
  • Merck has acquired an exclusive option to negotiate a separate agreement for Geron's dendritic cell-based telomerase vaccine, which is currently in phase I/II clinical trials at Duke University Medical Center.
  • Geron will continue development of its dendritic cell-based vaccine product, with the goal of demonstrating its efficacy and tolerability.
  • The alliance reflects Merck's recognition of telomerase as an important cancer target and Geron's recognition of the strength of Merck's vaccine platform.
  • Dr. Thomas Okarma, President and CEO of Geron, stated that the decision to collaborate with Merck was an easy one, citing the company's focus and commitment to developing cancer vaccines.
  • Dr. Stephen Friend, Executive Vice President at Merck Research Laboratories, expressed Merck's excitement about Geron's work on telomerase in cancer and stated that the project is of high interest and commitment at Merck.

Statistics:

  • The exclusive option pay-out from Merck to Geron was not disclosed.
  • Geron's dendritic cell-based vaccine product is currently in phase I/II clinical trials at Duke University Medical Center.
  • The collaboration aims to demonstrate the efficacy and tolerability of a potential vaccine against telomerase using Merck's platform.
  • Merck has acquired an equity stake in Geron as part of Geron's next round of financing, but the exact percentage was not disclosed.

Sources:

  • "Geron Corp. and Merck & Co. Enter Collaboration and License Agreement to Develop Cancer Vaccine Targeting Telomerase," Biotech Business Week via NewsRx.com, 2005.

Read more